Lufeng Li
Overview
Explore the profile of Lufeng Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Song S, Li L, Yuan Z, Li Y
Sci Rep
. 2025 Feb;
15(1):5032.
PMID: 39934289
No abstract available.
2.
Li X, He A, Liu B, Shan R, Zhu J, Li X, et al.
Front Endocrinol (Lausanne)
. 2024 Aug;
15:1407829.
PMID: 39170740
Background: To assess the bioequivalence between Gan & Lee (GL) glargine U300 and Toujeo regarding pharmacokinetics (PK), pharmacodynamics (PD), and safety in Chinese healthy male participants. Methods: A single-center, randomized,...
3.
Zhang X, Zhang S, Zhang H, Xiong Z, Li Y, Li L, et al.
J Cancer Educ
. 2024 Jun;
39(5):520-529.
PMID: 38898222
Previous studies have proved that healthy behaviors hinder the onset and progression of tumors. Digital therapeutics (DTx), playing a pivotal role in facilitating behavioral adjustments through educational interventions, lifestyle support,...
4.
Yang Z, Song S, Li L, Yuan Z, Li Y
Sci Rep
. 2024 Jun;
14(1):13801.
PMID: 38877074
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a predominant liver disease worldwide, lacking approved drugs for clinical intervention at present. The composite dietary antioxidant index (CDAI) is used...
5.
Li H, Shan R, Ding J, Zhang J, Liu B, Ge Q, et al.
Expert Opin Drug Metab Toxicol
. 2023 Dec;
19(12):1015-1021.
PMID: 38059472
Objectives: To compare the pharmacokinetic and safety of the test group capecitabine tablets (0.5 g) and the reference group capecitabine tablets (0.5 g). Methods: This study was registered at www.chinadrugtrials.org.cn...
6.
Li L, Liu W, Mao Q, Zhou D, Ai K, Zheng W, et al.
Oxid Med Cell Longev
. 2022 Nov;
2022:7192507.
PMID: 36338347
Vascular calcification (VC) is regarded as a common feature of vascular aging. Klotho deficiency reportedly contributes to VC, which can be ameliorated by restoration of Klotho expression. However, the specific...
7.
Yang Q, Li J, Zhang Z, Wu X, Liao T, Yu S, et al.
BMC Infect Dis
. 2021 Aug;
21(1):783.
PMID: 34372767
Background: The novel coronavirus disease 2019 (COVID-19) spreads rapidly among people and causes a pandemic. It is of great clinical significance to identify COVID-19 patients with high risk of death....
8.
Zhao N, Chen Z, Zhou Y, Xu Q, Xu Z, Tong W, et al.
Angiology
. 2020 Sep;
72(2):145-152.
PMID: 32911955
Iodixanol is associated with lower rates of contrast-induced acute kidney injury (CI-AKI). However, the effects of high volumes of iodixanol on renal function after percutaneous coronary intervention (PCI) have not...
9.
Mao Q, Zhao N, Wang Y, Li Y, Xiang C, Li L, et al.
Biomed Res Int
. 2019 Jul;
2019:8541402.
PMID: 31317040
Objective: The underlying mechanisms by which cystatin C affects cardiovascular disease (CVD) are not very clear. Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of...
10.
Zheng W, Li Y, Tian J, Li L, Xie L, Mao Q, et al.
Biomed Res Int
. 2019 Apr;
2019:3170957.
PMID: 31016189
Background: Percutaneous treatment of coronary bifurcation lesions can potentially lead to higher risk of ischemic events than the nonbifurcation ones, thus calling for further optimization of dual antiplatelet therapy (DAPT)....